Published in Medical Patent Week, May 9th, 2010
This is the first patent granted of a large estate filed by Amira Pharmaceuticals that describe novel small molecule inhibitors of the DP2 (CRTH2) receptor. Amira has successfully completed Phase 1 studies on its lead DP2 receptor antagonist, AM211, and anticipates that this compound will be developed for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and other allergic conditions.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week